ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

NCT03249714 ·Status: COMPLETED ·Phase: PHASE2

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis

NCT06159712 ·Status: RECRUITING ·Phase: NA

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

NCT05334472 ·Status: COMPLETED

Characterizing the Use of Ofatumumab in a Real World Setting

NCT05090033 ·Status: COMPLETED

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

NCT04940065 ·Status: COMPLETED

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

NCT05776888 ·Status: ACTIVE_NOT_RECRUITING

COMparison Between All immunoTherapies for Multiple Sclerosis.

NCT03193866 ·Status: COMPLETED

A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data

NCT06854341 ·Status: COMPLETED

Imatinib for Multiple Sclerosis (MS) Relapses

NCT03674099 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657 ·Status: COMPLETED

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

NCT06869785 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 ·Status: RECRUITING ·Phase: PHASE3

Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

NCT06668324 ·Status: COMPLETED

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

NCT04788615 ·Status: COMPLETED ·Phase: PHASE3

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

NCT06551519 ·Status: RECRUITING

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02861014 ·Status: COMPLETED ·Phase: PHASE3

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

NCT05576779 ·Status: COMPLETED

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

NCT00640328 ·Status: COMPLETED ·Phase: PHASE2

RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies

NCT06267781 ·Status: RECRUITING

An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis

NCT05214794 ·Status: COMPLETED ·Phase: PHASE2

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072 ·Status: COMPLETED

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

NCT04486716 ·Status: COMPLETED ·Phase: PHASE3

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT05658601 ·Status: COMPLETED

Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

NCT06737419 ·Status: COMPLETED